The "Nitazene Control Act" aims to permanently classify the dangerous class of synthetic opioids known as nitazenes under Schedule I of the Controlled Substances Act. These benzimidazole-opioids are recognized for their extreme potency, often exceeding that of fentanyl, and their significant contribution to overdose deaths in the United States due to their emergence in the illicit drug supply. The bill amends the Controlled Substances Act by adding a new category to Schedule I specifically for nitazenes, defining them by their distinct chemical structure and their agonist activity at the mu-opioid receptor. This class-wide scheduling is intended to preemptively address the rapid emergence of new nitazene analogs, streamline enforcement efforts, and convert any temporarily scheduled nitazene compounds to permanent Schedule I status upon enactment. To ensure continuity of vital scientific work, the legislation includes a temporary research exemption for studies involving newly scheduled nitazenes that were already underway before the Act's passage. This exemption, lasting up to 18 months, allows researchers to apply for the necessary registrations without immediately halting their approved, ongoing investigations, provided they meet specific criteria and notify the Attorney General.